Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01153425 · ClinicalTrials.gov registry record · Phase 4
µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT01153425: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT01153425 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01153425, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to apply a novel advanced magnetic resonance imaging methodology to evaluate the response to drug intervention involving two treatment arms of postmenopausal participants with osteoporosis, randomized into either a teriparatide (Forteo™) or zoledronic acid (Reclast™) group.
Interventions
- DRUG Zoledronic Acid
- DRUG Teriparatide
- OTHER Virtual Bone Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01153425
The ClinicalTrials.gov registry entry for NCT01153425 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zoledronic Acid is the first listed.
NCT01153425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01153425 about?
NCT01153425 is a clinical study titled "µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis". The purpose of this study is to apply a novel advanced magnetic resonance imaging methodology to evaluate the response to drug intervention involving two treatment arms of postmenopausal participants with osteoporosis, randomized into either a teriparatide (Forteo™) or zoledronic acid (Reclast™) gro...
What is the current status of trial NCT01153425?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2008-07. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01153425?
The interventions under investigation include: Zoledronic Acid (DRUG), Teriparatide (DRUG), Virtual Bone Biopsy (OTHER).
Who is sponsoring clinical trial NCT01153425?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.